Short description:
Targeted Protein Degraders
Drug notes:
Contact us to add description: recruit@workinbiotech.com
Long description:
76Bio, founded in 2020, is developing therapies that target unnecessary proteins for degradation in treatment of various life-threatening diseases. The team has backgrounds in immunology, oncology, biology, and genetics. CEO, Christopher Wilfong, previously co-founded and held leadership positions at other Two River companies, including Kite Pharma, Kronos Bio, and Neogene Therapeutics. 76Bio’s R&D headquarters is located in Boston, MA.